Evaxion Adds AI-Designed Brain Cancer Vaccine to Pipeline, Discontinues EVX-03
Event summary
- Evaxion launches EVX-05, an AI-designed off-the-shelf vaccine targeting glioblastoma, a deadly brain cancer.
- The program leverages Evaxion’s AI-Immunology™ platform to identify novel conserved antigens from patient tumor samples.
- Collaboration with Duke University School of Medicine will conduct initial clinical testing of EVX-05.
- EVX-05 replaces the discontinued EVX-03 program, with costs absorbed within existing budgets.
- Evaxion maintains cash runway into the second half of 2027.
The big picture
Evaxion’s shift to EVX-05 reflects a strategic pivot toward AI-driven cancer vaccines, particularly in high-unmet-need areas like glioblastoma. The collaboration with Duke University underscores the importance of academic partnerships in accelerating clinical development. This move aligns with broader industry trends where biotech firms leverage AI for faster, more precise drug discovery, though execution risks remain high in translating promising preclinical data into clinical success.
What we're watching
- Clinical Progress
- How quickly EVX-05 advances through clinical testing under Duke University’s leadership.
- Pipeline Strategy
- Whether Evaxion can sustain momentum with its refocused pipeline after discontinuing EVX-03.
- Financial Sustainability
- The pace at which Evaxion burns through its cash runway into 2027.
Related topics